Background There is scant data about small children receiving protease inhibitor (PI)-based therapy in real-life resource-limited configurations and on the perfect timing of therapy among kids who survive infancy. antiretrovirals (ARVs). Among babies improved success was connected with male gender (HRdeath 0.54 95 CI 0.32-0.92) and treatment with highly dynamic antiretroviral therapy (HAART) (HRdeath 0.32… Continue reading Background There is scant data about small children receiving protease inhibitor